期刊： CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2023; 38 (2)
Background: Previous studies have reported the use of microRNAs (miRNAs) as diagnostic and/or prognostic biomarkers for various cancers, including gas......
期刊： CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2023; 38 (9)
Background: Osteosarcoma (OS) is a common, aggressive primary sarcoma of bone. Drug resistance is a huge obstacle to chemotherapy for cancer. This stu......
期刊： CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2023; 38 (4)
A 73-year-old female patient, affected by mycosis fungoides (MF), discontinued mogamulizumab, after initial clinical benefit, due to the onset of gene......
期刊： CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2023; 38 (1)
Imagine a theranostic nuclear physician oncologist engaged in a Socratic philosophic dialogue. Questions that may be posed include the status of our c......
期刊： CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2023; 38 (8)
Multidisciplinary tumor boards (MTBs) have become the reference standard of cancer management, founded upon randomized controlled trial (RCT) evidence......
期刊： CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2023; 38 (2)
Background: The purpose of this study was to investigate the effect of oral nutritional supplements (ONS) on patients with esophageal cancer during ra......
期刊： CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2023; 38 (4)
In the past decade, the implementation of immunotherapy with checkpoint inhibitors has determined a major change in the management of oncological pati......
期刊： CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2023; 38 (5)
Objective: The role and molecular mechanism of long-chain noncoding RNAs (lncRNAs) in lung cancer remain to be elucidated. The aim of this study was t......
期刊： CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2023; 38 (3)
Systems biology approach, carried out with high-throughput omics technologies, has become a fundamental aspect of the study of complex diseases like c......
期刊： CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2023; 38 (6)
Objective: In this study, the authors identified miR-193a-3p as a tumor-suppressing microRNA, and its effects on the chemosensitivity to trametinib in......
期刊： CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2023; 38 (4)
Introduction: Lung cancer (LC) is a leading cause of death among men and women, with non-small cell LC (NSCLC) accounting for a substantial portion of......
期刊： CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2023; 38 (5)
Background: Lung adenocarcinoma (LAC) is a common malignancy worldwide. Emerging findings indicated that circular RNAs possess complex capacities of g......
期刊： CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2023; 38 (8)
Background: 2',3'-cGAMP (2',3'-cyclic AMP-GMP) has been reported as an agonist of the STING (stimulator of interferon genes) signaling pathway. Howeve......
期刊： CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2023; 38 (1)
Background: Temozolomide (TMZ) resistance plays a critical role in the treatment of glioma. This research tries to explore how circRNAs affect the che......
期刊： CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2023; 38 (6)
Purpose: To evaluate the impact of neutrophil-to-lymphocyte ratio (NLR) and preoperative prognostic nutritional index (PNI) on prognosis of gastric ca......
